Kedrion, an italian biopharmaceutical champion
Kedrion is an Italian group and one of the world’s leading companies in plasma-derived medicines, active in the development and production of therapies for the treatment of serious, rare and ultra-rare diseases.
The Group operates through seven manufacturing plants and a network of around 80 plasma collection centres, and markets its products in more than 100 countries.
CDP Equity has supported Kedrion’s growth since 2012, backing its international expansion, the development of new therapies and the strengthening of its production capacity. The investment has helped create a global leader in the sector, culminating in the acquisition of BPL, while consolidating a strategic, high-tech supply chain and keeping Italy at the heart of the Group’s industrial and manufacturing operations.
Learn more
